Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960854 · ClinicalTrials.gov registry record · Phase 1
A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
A Phase 1 study of Severe Sepsis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 16
- Study locations
NCT02960854 is a Phase 1 study of Severe Sepsis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 38 participants, below the 6,207-participant average among 9 other Severe Sepsis trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 13 states.
The verdict
NCT02960854, a Phase 1 study of Severe Sepsis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 16
- Study locations
Study Summary
A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
Study Locations (16)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center (BIDMC) - Boston
- Baystate Medical Center - Springfield
Colorado
- Univ. Of Colorado Health - Colorado Springs
- Denver Health Medical Center - Denver
California
- Uc Davis Medical Center - Sacramento
Florida
- University Of Florida - Gainesville
Georgia
- Pulmonary And Critical Care Of Atlanta - Atlanta
Illinois
- Osf Saint Francis Medical Center - Peoria
Kentucky
- University Of Kentucky - Lexington
Michigan
- University of Michigan, Division of Acute Care Surgery - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-12-07 |
| Est. Completion | 2018-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960854
The ClinicalTrials.gov registry entry for NCT02960854 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,207-participant average among 9 other Severe Sepsis trials with a reported enrollment target (99% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT02960854 reports 16 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, Colorado, California.
Frequently Asked Questions
What is clinical trial NCT02960854 about?
NCT02960854 is a clinical study titled "A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.". A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
What is the current status of trial NCT02960854?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2016-12-07. Estimated completion is 2018-01-05.
What conditions does trial NCT02960854 study?
This clinical trial studies the following conditions: Severe Sepsis.
What interventions are being tested in trial NCT02960854?
The interventions under investigation include: Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02960854?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02960854 being conducted?
This trial has 16 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zinc Therapy in Critical Illness
ACTIVE NOT RECRUITING · Phase 1
-
Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia
ACTIVE NOT RECRUITING
-
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
COMPLETED
-
Predictive algoRithm for EValuation and Intervention in SEpsis
COMPLETED · NA
-
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)
COMPLETED · Phase 2
-
Ultrasound Measurement of Reactive Hyperemia in Critical Care
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.